基于口-肠-肝轴理论探讨原发性肝癌的新型治疗策略

周铖; 张佳铭; 郭礼; 司海龙; 肖海娟; 杨林

doi:10.3969/j.issn.1001-5256.2020.07.044

基于口-肠-肝轴理论探讨原发性肝癌的新型治疗策略

DOI: 10.3969/j.issn.1001-5256.2020.07.044

1. 陕西中医药大学第一临床医学院
2. 浙江中医药大学第二临床医学院
3. 陕西中医药大学附属医院肿瘤三科
4. 空军军医大学西京消化病医院肿瘤生物学国家重点实验室
5. 陕西中医药大学附属咸阳中心医院肝胆外科

基金项目:

中国博士后科学基金面上项目(2017M613351)；陕西中医药大学创新团队(2019-YL06)；陕西省自然科学基金项目(2018JQ8014)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 666
- HTML全文浏览量: 15
- PDF下载量: 137
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

A new treatment strategy for primary liver cancer based on the theory of the oral-gut-liver axis

1. The First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China; 2. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310000, China; 3. The Third Department of Oncology, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China; 4. State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi’an 710032, China; 5. Department of Hepatobiliary Surgery, Xianyang Central Hospital Affiliated to Shaanxi University of Chinese Medicine, Xiangyang, Shaanxi 712000, China

Research funding:

摘要

摘要: 原发性肝癌的潜在病因繁多且起病隐匿,病情的进展受多方面因素影响。免疫治疗与靶向药物治疗一直是作为肝癌常规的非根治性治疗方法,但疗效并不理想,耐药情况不容乐观。近年来16s高通量测序技术的广泛应用与微生物组学的不断深入研究,揭示了微生物在肝癌发生发展中的关键作用。肝脏与口腔、肠道菌群的联系逐渐明确,口腔与肠道的菌群调控为该病开辟了新的治疗方法。综述了口-肠-肝轴的微生物理论基础及其在原发性肝癌治疗上的应用和发展方向。
- 肝肿瘤 /
- 微生物群 /
- 益生元
Abstract: Primary liver cancer has various potential causes and insidious onset,and its progression is affected by many factors. Immunotherapy and targeted drug therapy have been used as non-radical treatment methods for primary liver cancer,but they cannot achieve a satisfactory effect and may lead to drug resistance. In recent years,the wide application of 16 s high-throughput sequencing and the in-depth studies of microbiology have revealed the key role of microorganisms in the development and progression of liver cancer. The association of the liver with oral and intestinal flora is gradually clarified,and the regulation of oral and intestinal flora has brought new treatment methods for the disease. This article reviews the microbial theory of the oral-gut-liver axis and its application and development in the treatment of primary liver cancer.
- liver neoplasms /
- microbiota /
- prebiotics

HTML全文

参考文献(45)

[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424．

[2]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132．

[3] GARRETT WS.Cancer and the microbiota[J].Science,2015,348(6230):80-86．

[4] ARTHUR JC,GHARAIBEH RZ,MHLBAUER M,et al.Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer[J].Nat Commun,2014,5:4724．

[5] BOLEIJ A,HECHENBLEIKNER EM,GOODWIN AC,et al.The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients[J].Clin Infect Dis,2015,60(2):208-215．

[6]GUERRA L,GUIDI R,FRISAN T.Do bacterial genotoxins contribute to chronic inflammation,genomic instability and tumor progression?[J].FEBS J,2011,278(23):4577-4588．

[7]XU X,HE J,XUE J,et al.Oral cavity contains distinct niches with dynamic microbial communities[J].Environ Microbiol,2015,17(3):699-710．

[8] HAN YW,FARDINI Y,CHEN C,et al.Term stillbirth caused by oral Fusobacterium nucleatum[J].Obstet Gynecol,2010,115(2 Pt2):442-445．

[9] VEGA-VILLA K,PLUTA R,LONSER R,et al.Quantitative systems pharmacology model of no metabolome and methemoglobin following long-term infusion of sodium nitrite in humans[J].CPT Pharmacometrics Syst Pharmacol,2013,2:e60．

[10] OHTANI N,KAWADA N.Role of the gut-liver axis in liver inflammation,fibrosis,and cancer:A special focus on the gut microbiota relationship[J].Hepatol Commun,2019,3(4):456-470．

[11] STALEY C,WEINGARDEN AR,KHORUTS A,et al.Interaction of gut microbiota with bile acid metabolism and its influence on disease states[J].Appl Microbiol Biotechnol,2017,101(1):47-64．

[12] PETERSON LW,ARTIS D.Intestinal epithelial cells:Regulators of barrier function and immune homeostasis[J].Nat Rev Immunol,2014,14(3):141-153．

[13] PONZIANI FR,BHOORI S,CASTELLI C,et al.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J].Hepatology,2019,69(1):107-120．

[14] JAISWAL G,DEO V,BHONGADE M,et al.Serum alkaline phosphatase:A potential marker in the progression of periodontal disease in cirrhosis patients[J].Quintessence Int,2011,42(4):345-348．

[15] LU H,REN Z,LI A,et al.Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma[J].Sci Rep,2016,6:33142．

[16]HAN P,SUN D,YANG J.Interaction between periodontitis and liver diseases[J].Biomed Rep,2016,5(3):267-276．

[17]WANG Z,REN Z,CHEN Y,et al.Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection:A randomized controlled study[J].Clin Cancer Res,2018,24(9):2074-2081．

[18]ZHU PL,YIN C,FENG JL.Progress in comprehensive treatment of primary liver cancer[J].J Clin Hepatol,2015,31(6):965-968.(in Chinese)祝普利，尹超，冯建龙．原发性肝癌综合治疗进展[J]．临床肝胆病杂志，2015,31(6):965-968．

[19] LI L,ZHANG J,LIU X,et al.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma:Ameta-analysis[J].J Gastroenterol Hepatol,2012,27(1):51-58．

[20]HUANG J,YAN L,CHENG Z,et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J].Ann Surg,2010,252(6):903-912．

[21] Bureau of Medical Administration,National Health Commission of the People's Republic of China.Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J].J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292．

[22]ZHU AX,FINN RS,EDELINE J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase2 trial[J].Lancet Oncol,2018,19(7):940-952．

[23] JACKSON R,PSARELLI EE,BERHANE S,et al.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer:A meta-analysis of randomized phase III trials[J].J Clin Oncol,2017,35(6):622-628．

[24]ATARASHI K,SUDA W,LUO C,et al.Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation[J].Science,2017,358(6361):359-365．

[25]LINS L,BITTENCOURT PL,EVANGELISTA MA,et al.Oral health profile of cirrhotic patients awaiting liver transplantation in the Brazilian Northeast[J].Transplant Proc,2011,43(4):1319-1321．

[26] YONEDA M,NAKA S,NAKANO K,et al.Involvement of a periodontal pathogen,Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease[J].BMC Gastroenterol,2012,12:16．

[27]CHEN B,YAN FH.Non-surgical therapy in advanced periodontitis[J].Chin J Practical Stomatology,2016,9(4):197-201.(in Chinese)陈斌，闫福华．重度牙周炎非手术治疗[J]．中国实用口腔科杂志，2016,9(4):197-201．

[28]OKUSHIN K,TSUTSUMI T,IKEUCHI K,et al.Helicobacter pylori infection and liver diseases:Epidemiology and insights into pathogenesis[J].World J Gastroenterol,2018,24(32):3617-3625．

[29]WIJARNPREECHA K,THONGPRAYOON C,PANJAWATANAN P,et al.Helicobacter pylori and risk of nonalcoholic fatty liver disease:A systematic review and Meta-analysis[J].J Clin Gastroenterol,2018,52(5):386-391．

[30] CHANG B,SANG L,WANG Y,et al.The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury[J].BMC Gastroenterol,2013,13:151．

[31]KUMAR M,VERMA V,NAGPAL R,et al.Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB1-induced hepatocellular carcinoma[J].Gene,2011,490(1-2):54-59．

[32]FERRERE G,WRZOSEK L,CAILLEUX F,et al.Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice[J].J Hepatol,2017,66(4):806-815．

[33]ZONG DW,GUO CY,CHENG HT,et al.Influence of lactulose on interventional therapy for HCC patients with hepatocirrhosis and hypersplenism[J].Asian Pac J Trop Med,2016,9(2):193-196．

[34]KELLY CR,KAHN S,KASHYAP P,et al.Update on fecal microbiota transplantation 2015:Indications,methodologies,mechanisms,and outlook[J].Gastroenterology,2015,149(1):223-237．

[35] BAJAJ JS,KASSAM Z,FAGAN A,et al.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J].Hepatology,2017,66(6):1727-1738．

[36] WEINGARDEN AR,DOSA PI,DEWINTER E,et al.Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control clostridium difficile germination and growth[J].PLo S One,2016,11(1):e0147210．

[37]ZHOU C,SUN PF,YIN JY,et al.Evolution of clinical treatment in inflammatory bowel diseases by fecal microbiota transplantation[J].JShanghai Jiaotong Uni(Med Sci),2020,40(2):267-270.(in Chinese)周铖，孙鹏飞，尹继瑶，等．粪菌移植治疗炎症性肠病的研究进展[J]．上海交通大学学报(医学版)，2020,40(2):267-270．

[38]PENG PL,ZHOU XY.Risk factors and prognosis of esophagogastric variceal bleeding in liver cirrhosis[J].J Clin Med Pract,2016,20(9):171-173.(in Chinese)彭湃澜，周翔禹．肝硬化食管胃底静脉曲张破裂出血的危险因素及预后分析[J]．实用临床医药杂志，2016,20(9):171-173．

[39]LI N,ZHAO YM,CHEN ZY,et al.Dynamic effects of antibioticinduced intestinal dysbacteriosis on intestinal mucosa barrier and liver function[J].Chin J Anim Nutrition,2019,31(3):1278-1287.(in Chinese)李娜，赵玉民，陈正元，等．抗生素诱导肠道菌群失调对肠黏膜屏障和肝脏功能的动态影响[J]．动物营养学报，2019,31(3):1278-1287．

[40]XU D,GAO J,GILLILLAND M 3rd,et al.Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats[J].Gastroenterology,2014,146(2):484-496.e4．

[41] CALANNI F,RENZULLI C,BARBANTI M,et al.Rifaximin:Beyond the traditional antibiotic activity[J].J Antibiot(Tokyo),2014,67(9):667-670．

[42] YU LX,SCHWABE RF.The gut microbiome and liver cancer:Mechanisms and clinical translation[J].Nat Rev Gastroenterol Hepatol,2017,14(9):527-539．

[43] WANG Y,CAI J,ZENG X,et al.Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling[J].BMC Cancer,2015,15:821．

[44] FULDE M,SOMMER F,CHASSAING B,et al.Neonatal selection by Toll-like receptor 5 influences long-term gut microbiota composition[J].Nature,2018,560(7719):489-493．

[45] INGERSOLL MA,ALBERT ML.From infection to immunotherapy:Host immune responses to bacteria at the bladder mucosa[J].Mucosal Immunol,2013,6(6):1041-1053.

施引文献

资源附件(0)

访问统计